Stater Bros. is replacing its previous manual ordering processes with its use of Afresh's AI-powered solution, and measured significant improvements during the pilot.

What a difference 60 weeks can make. That’s the lesson Akero Therapeutics Inc. shared with the rollout of what executives called “unprecedented” data from the phase IIb Symmetry trial testing ...

(ETNB) stock jumped 40% Monday, stoked by positive data for Akero's (AKRO) drug efruxifermin in the treatment of compensated ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the ...

MicroStrategy is the largest corporate holder of Bitcoin in the world and now holds 471,107 BTC worth over $48 billion. The ...

Akero Therapeutics (AKRO) stock soared 115% after the company reported positive long-term results from a Phase 2b study of ...

Akero reported Monday strong results showing its drug efruxifermin reversed liver scarring in patients with cirrhosis caused ...

Some SAST tools provide better insight into all potential vulnerabilities and coding issues, while others offer a better ...

First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...

Dr. Scott Kopetz discusses the BREAKWATER trial investigating Braftovi and Erbitux plus chemo in those with BRAF V600E+ ...